Skip to main content
Top
Published in: Annals of Surgical Oncology 3/2014

01-03-2014 | Hepatobiliary Tumors

Assessing Prognostic Significance of Preoperative Alpha-Fetoprotein in Hepatitis B-Associated Hepatocellular Carcinoma: Normal is not the New Normal

Authors: Sima Blank, MS, Qin Wang, PhD, M. Isabel Fiel, MD, Wei Luan, MD, Ki Won Kim, MD, Hena Kadri, BA, John Mandeli, PhD, Spiros P. Hiotis, MD, PhD

Published in: Annals of Surgical Oncology | Issue 3/2014

Login to get access

Abstract

Background

Hepatitis B (HBV)-associated hepatocellular carcinoma (HCC) is often associated with alpha-fetoprotein (AFP) production. Although serum AFP has been demonstrated to be a prognostic factor for patient survival, optimal cutoff levels remain unclear.

Methods

Patients with HBV-associated HCC treated by primary liver resection were prospectively followed at a single institution between 1995 and 2008. AFP level was categorized into quintiles for Kaplan–Meier analysis and multivariable Cox proportional hazards regression models.

Results

Best 5-year survival after surgery was observed for patients with AFP in the first quintile (1.4–4.1 ng/mL), with progressively worse outcomes for patients in each increasing quintile. AFP was associated with overall survival (HR = 1.61; 95 % CI 1.30–1.98), disease-free survival (HR = 1.26; 95 % CI 1.10–1.44), and 2-year recurrence (HR = 1.30; 95 % CI 1.07–1.57) in multivariate analysis. Noncirrhotic patients (Ishak 1–5) with AFP in quintile 1 had 94 % 5-year survival, compared with 0 % survival for patients with AFP in quintile 5 (2,332.7–327,560.0 ng/mL) and Ishak stage 6 cirrhosis.

Conclusions

Preoperative serum AFP is an independent predictor of prognosis among HBV-HCC patients following surgical resection. Categorizing AFP into quintiles creates the opportunity to observe differences in outcomes even at low serum levels within the normal range. Additionally, combining AFP quintiles and fibrosis staging provides a predictive model of prognosis for HCC. Thus, even small differences in AFP within the normal range may impact prognosis and disease progression for HBV-HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
2.
go back to reference Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239–45.PubMedCrossRef Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239–45.PubMedCrossRef
3.
go back to reference Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.PubMedCrossRef Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.PubMedCrossRef
4.
go back to reference Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30:3–16.PubMedCrossRef Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30:3–16.PubMedCrossRef
6.
7.
go back to reference Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci. 1992;303:157–9.PubMedCrossRef Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci. 1992;303:157–9.PubMedCrossRef
8.
go back to reference Alpert ME, Uriel J, de Nechaud B. Alpha-1 fetoglobulin in the diagnosis of human hepatoma. New Engl J Med. 1968;278:984–6.PubMedCrossRef Alpert ME, Uriel J, de Nechaud B. Alpha-1 fetoglobulin in the diagnosis of human hepatoma. New Engl J Med. 1968;278:984–6.PubMedCrossRef
9.
go back to reference Paul SB, Gulati MS, Sreenivas V, Madan K, Gupta AK, Mukhopadhyay S, et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology. 2007;72 Suppl 1:117–23.PubMedCrossRef Paul SB, Gulati MS, Sreenivas V, Madan K, Gupta AK, Mukhopadhyay S, et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology. 2007;72 Suppl 1:117–23.PubMedCrossRef
10.
go back to reference Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127:S108–112.PubMedCrossRef Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127:S108–112.PubMedCrossRef
12.
go back to reference Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–6.PubMedCrossRef Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–6.PubMedCrossRef
13.
go back to reference Lee SS, Shin HS, Kim HJ, Lee SJ, Lee HS, Hyun KH, et al. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol. 2012;18:48–55.PubMedCentralPubMedCrossRef Lee SS, Shin HS, Kim HJ, Lee SJ, Lee HS, Hyun KH, et al. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol. 2012;18:48–55.PubMedCentralPubMedCrossRef
14.
go back to reference Lerose R, Molinari R, Rocchi E, Manenti F, Villa E. Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer. 2001;37:239–45.PubMedCrossRef Lerose R, Molinari R, Rocchi E, Manenti F, Villa E. Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer. 2001;37:239–45.PubMedCrossRef
15.
go back to reference Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004;112:44–50.PubMedCrossRef Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004;112:44–50.PubMedCrossRef
16.
17.
go back to reference Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31:302–8.PubMedCrossRef Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31:302–8.PubMedCrossRef
18.
go back to reference Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of alpha-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:989–94.PubMedCentralPubMedCrossRef Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of alpha-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:989–94.PubMedCentralPubMedCrossRef
19.
go back to reference Zhang XF, Meng B, Qi X, Yu L, Liu C, Liu XM, et al. Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: surgeon’s role in survival. Eur J Surg Oncol. 2009;35:622–8.PubMedCrossRef Zhang XF, Meng B, Qi X, Yu L, Liu C, Liu XM, et al. Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: surgeon’s role in survival. Eur J Surg Oncol. 2009;35:622–8.PubMedCrossRef
20.
go back to reference Nanashima A, Taura N, Abo T, Ichikawa T, Sakamoto I, Nagayasu T, et al. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci. 2011;56:3086–100.PubMedCrossRef Nanashima A, Taura N, Abo T, Ichikawa T, Sakamoto I, Nagayasu T, et al. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci. 2011;56:3086–100.PubMedCrossRef
21.
go back to reference Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008;49:223–32.PubMedCrossRef Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008;49:223–32.PubMedCrossRef
22.
go back to reference Shim JH, Yoon DL, Han S, Lee YJ, Lee SG, Kim KM, et al. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann Surg Oncol. 2012;19:3687–96.PubMedCrossRef Shim JH, Yoon DL, Han S, Lee YJ, Lee SG, Kim KM, et al. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann Surg Oncol. 2012;19:3687–96.PubMedCrossRef
23.
go back to reference Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012;56:1371–9.PubMedCrossRef Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012;56:1371–9.PubMedCrossRef
24.
go back to reference Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q, et al. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol. 2012;12:64.PubMedCentralPubMedCrossRef Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q, et al. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol. 2012;12:64.PubMedCentralPubMedCrossRef
25.
go back to reference Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, et al. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer. 2013;109:573–81.PubMedCrossRef Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, et al. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer. 2013;109:573–81.PubMedCrossRef
26.
go back to reference Wang Q, Fiel MI, Luan W, Blank S, Kadri H, Kim KW, et al. Impact of intrahepatic hepatitis B DNA and covalently closed circular DNA on survival after hepatectomy in HBV-associated hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20:3761–70.PubMedCrossRef Wang Q, Fiel MI, Luan W, Blank S, Kadri H, Kim KW, et al. Impact of intrahepatic hepatitis B DNA and covalently closed circular DNA on survival after hepatectomy in HBV-associated hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20:3761–70.PubMedCrossRef
27.
go back to reference Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol. 2006;101:524–32.PubMedCrossRef Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol. 2006;101:524–32.PubMedCrossRef
28.
go back to reference Huo TI, Huang YH, Lui WY, Wu JC, Lee PC, Chang FY, et al. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep. 2004;11:543–50.PubMed Huo TI, Huang YH, Lui WY, Wu JC, Lee PC, Chang FY, et al. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep. 2004;11:543–50.PubMed
29.
go back to reference Xie Z, Zhang H, Tsai W, Zhang Y, Du Y, Zhong J, et al. Zinc finger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver. Proc Natl Acad Sci USA. 2008;105:10859–64.PubMedCrossRef Xie Z, Zhang H, Tsai W, Zhang Y, Du Y, Zhong J, et al. Zinc finger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver. Proc Natl Acad Sci USA. 2008;105:10859–64.PubMedCrossRef
30.
go back to reference Crowe AJ, Sang L, Li KK, Lee KC, Spear BT, Barton MC. Hepatocyte nuclear factor 3 relieves chromatin-mediated repression of the alpha-fetoprotein gene. J Biol Chem. 1999;274:25113–20.PubMedCrossRef Crowe AJ, Sang L, Li KK, Lee KC, Spear BT, Barton MC. Hepatocyte nuclear factor 3 relieves chromatin-mediated repression of the alpha-fetoprotein gene. J Biol Chem. 1999;274:25113–20.PubMedCrossRef
31.
go back to reference Bois-Joyeux B, Danan JL. Members of the CAAT/enhancer-binding protein, hepatocyte nuclear factor-1 and nuclear factor-1 families can differentially modulate the activities of the rat alpha-fetoprotein promoter and enhancer. Biochem J. 1994;301:49–55.PubMed Bois-Joyeux B, Danan JL. Members of the CAAT/enhancer-binding protein, hepatocyte nuclear factor-1 and nuclear factor-1 families can differentially modulate the activities of the rat alpha-fetoprotein promoter and enhancer. Biochem J. 1994;301:49–55.PubMed
32.
go back to reference Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, et al. MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun. 2011;2:338.PubMedCrossRef Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, et al. MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun. 2011;2:338.PubMedCrossRef
33.
go back to reference Ogden SK, Lee KC, Barton MC. Hepatitis B viral transactivator HBx alleviates p53-mediated repression of alpha-fetoprotein gene expression. J Biol Chem. 2000;275:27806–14.PubMed Ogden SK, Lee KC, Barton MC. Hepatitis B viral transactivator HBx alleviates p53-mediated repression of alpha-fetoprotein gene expression. J Biol Chem. 2000;275:27806–14.PubMed
34.
go back to reference Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44:765–9.PubMedCrossRef Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44:765–9.PubMedCrossRef
35.
go back to reference Wu J-C, Huang Y-H, Chau G-Y, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890–7.PubMedCrossRef Wu J-C, Huang Y-H, Chau G-Y, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890–7.PubMedCrossRef
36.
go back to reference Chen Y-J, Yeh S-H, Chen J-T, Wu CC, Hsu MT, Tsai SF, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology. 2000;119:431–40.PubMedCrossRef Chen Y-J, Yeh S-H, Chen J-T, Wu CC, Hsu MT, Tsai SF, et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology. 2000;119:431–40.PubMedCrossRef
37.
go back to reference Vitale A, Navaglia F, Ramirez Morales R, Frigo AC, Basso D, D’Amico F, et al. Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. PLoS ONE. 2011;6:e23093.PubMedCentralPubMedCrossRef Vitale A, Navaglia F, Ramirez Morales R, Frigo AC, Basso D, D’Amico F, et al. Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. PLoS ONE. 2011;6:e23093.PubMedCentralPubMedCrossRef
38.
go back to reference Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 2002;50:881–5.PubMedCrossRef Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 2002;50:881–5.PubMedCrossRef
39.
go back to reference Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4:1528–36.PubMedCrossRef Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4:1528–36.PubMedCrossRef
Metadata
Title
Assessing Prognostic Significance of Preoperative Alpha-Fetoprotein in Hepatitis B-Associated Hepatocellular Carcinoma: Normal is not the New Normal
Authors
Sima Blank, MS
Qin Wang, PhD
M. Isabel Fiel, MD
Wei Luan, MD
Ki Won Kim, MD
Hena Kadri, BA
John Mandeli, PhD
Spiros P. Hiotis, MD, PhD
Publication date
01-03-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 3/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3357-z

Other articles of this Issue 3/2014

Annals of Surgical Oncology 3/2014 Go to the issue